Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Major Shifts in Urothelial Cancer Care: Immunotherapy Redefines Standards

2.

Global warming could be driving up women's cancer risk, find researchers

3.

Kate Middleton Gives Cancer Update

4.

In Advanced Myxoid Liposarcoma, Is Trabectedin Winning?

5.

In patients with advanced lung cancer, cemiplimab combined with chemotherapy extends life and enhances quality of life.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot